酶酚酸酯对实验性自身免疫性脑脊髓炎大鼠神经功能的影响

目的观察酶酚酸酯(MMF)对实验性自身免疫性脑脊髓炎(EAE)大鼠神经功能改善及脑脊髓组织的影响。方法用豚鼠全脊髓匀浆和完全弗氏佐剂制成的完全抗原免疫Wistar大鼠，制备EAE大鼠模型，以生理盐水和完全弗氏佐剂注射的Wistar大鼠作为对照。对照组大鼠7只，造模成功且存活的大鼠为25只，随机分为MMF大剂量组（n=8只）,MMF小剂量组（n=8只）,模型组（n=9只）。连续给药14d，每天观察记录神经功能评分及体重变化，14d后HE染色观察脑、脊髓组织病理变化。结果EAE大鼠的造模成功率为72.1%。与对照组相比，各组EAE大鼠神经功能评分明显增加，体重明显下降(P＜0.01)，脑脊髓组织病理学变化主要表现为血管周围有大量炎细胞浸润；与模型组相比，用MMF治疗后神经功能评分有所下降，体重增加，病理表现有不同程度的减轻，且大剂量MMF疗效优于小剂量MMF(P＜0.01)。结论MMF能改善EAE大鼠的症状，促进神经功能恢复，并具有剂量依赖性。

Effects of mycophenolate mofetil on neural function of experimental autoimmune encephalomyelitis in rats

Objective To explore the effects of mycophenolate mofetil on the improvement of neural function and brain and spine cord of rats with experimental autoimmune encephalomyelitis(EAE).Methods Wistar rats were induced by guinea pig spinal cord homogenate and complete freund adjuvant to establish EAE models,while the control rats were induced by saline and complete freund adjuvant.There were 7 control rats and 25 EAE rats which were successfully made and survived.The EAE rats were randomly divided into three groups: the high dose of mycophenolate mofetil treatment group(n=8),the low dose of mycophenolate mofetil treatment group(n=8),and the model group(n=9).Medicine was administered for 14 days and then the Duckers score and weight changes were assessed every day.After 14 days,pathological changes of brain and spine cord were observed by Hematoxylin and Eosin staining.Results The achievement ratio of the EAE model was 72.1%.Compared with the control group,the Duckers score of the EAE rats increased with a decrease of weight(P<0.01),pathological changes manifested inflammatory cells infiltration around vessels with HE staining. Compared with the model group,after treatment with mycophenolate mofetil,the Duckers score of the EAE rats decreased with an increase of weight and pathological changes lessened,moreover,the therapeutic effect of high dose mycophenolate mofetil was superior to low dose mycophenolate mofetil(P<0.01).Conclusion Mycophenolate mofetil can improve the symptoms of EAE rats and promotes the recovery of neural function in a dose-dependent manner.